- Clinical and translational research in lymphoma, with a focus on stem cell transplantation and development of novel therapies, as well as late effects of treatment
- Applied molecular oncology
Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
Leuk Lymphoma. 2019 Apr 18;:1-4
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Cancer Immunol Immunother. 2019 Feb 11;:
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
J Clin Oncol. 2019 Feb 11;:JCO1800915
Leuk Lymphoma. 2019 Jan 22;:1-10
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
Leuk Lymphoma. 2018 Oct 10;:1-8
Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
N Engl J Med. 2018 04 19;378(16):1559-60
New pricing approaches for bundled payments: Leveraging clinical standards and regional variations to target avoidable utilization.
Health Policy. 2016 Mar;120(3):316-26
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol. 2017 Dec 21;:
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Clin Cancer Res. 2016 Oct 01;22(19):4807-4816
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre